Dr Reddy’s is said to be the first company to launch an authorized generic version of Imitrex tablets in the US market. GlaxoSmithKline Imitrex tablets are indicated for the acute treatment of migraine attacks in adults.
Dr Reddy’s has previously announced that it had settled patent litigation with GlaxoSmithKline relating to sumatriptan succinate tablets, the generic version of GlaxoSmithKline Imitrex tablets. The specific financial terms and conditions of the settlement have not been disclosed.